Molecular Innovation, which
aims to discover and develop
novel therapeutics for human
diseases including lupus,
arthritis, diabetes, Alzheimer's
disease and sepsis. This
research integrates target
discovery with medicinal
chemistry to generate small
organic compounds and
potential drugs.
papillomatosis (RRP) is a
disease caused by the human
papillomavirus (HPV)--it is
the recurrence of tumors of
the upper airway that can
lead to airway blockages and
suffocation. Dr. Bonagura
studies the immune response
to HPV to understand why
RRP patients do not produce
the needed immune response
to prevent or control the virus.
and rheumatoid arthritis.
She is the clinical director
of the Feinstein Institute
Center for Clinical Research
in Autoimmune Disease and
co-director of the Clinical
Trials Unit. She conducts
studies to better understand
and develop treatments for
diseases such as lupus and
rheumatoid arthritis.
interests focus on malignant
brain tumor formation,
treatment and ways to
overcome resistance to
therapy. In addition to his
basic science interests, he
currently conducts multiple
clinical trials using blood-
brain barrier disruption
to deliver high-dose
chemotherapy for patients
with malignant brain tumors.
developmental erythropoiesis
and its impairment in
pathological conditions and
why genetic disorders in
erythroid development trigger
a cancer predisposition in
children, notably osteogenic
sarcoma.
is to discover and develop
better treatments for
patients with autoimmune
and inflammatory diseases.
Recent areas of focus include
rheumatoid arthritis and
inflammatory bowel disease.
research is to identify the
molecular factors necessary
to recover from central
nervous system (CNS) injury
or disease. Towards that goal,
her lab is investigating factors
that influence the course of
CNS injury or disease, as well
as the process to recover from
CNS injury or disease.
preclinical, translational
and phase I, II and III
clinical research in an effort
to determine new drug
developments for cancer.